3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
31
Phase 1
12
Phase 3
4
Phase NA
1
Phase EARLY_PHASE1
1
Phase 1/2
1
Status
Active not recruiting
2
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neoplasm Metastasis
2
Uveal Melanoma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Differentiated Thyroid Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
187
Carboplatin
182
Paclitaxel
177
Docetaxel
145
Cyclophosphamide
129
Dexamethasone
117
pembrolizumab
106
Doxorubicin
103
Bevacizumab
103
Gemcitabine
102
Rituximab
96
Prednisone
87
Fluorouracil
86
Pemetrexed
82
Radiotherapy
77
Vincristine
71
Etoposide
71
Capecitabine
69
Nivolumab
68
Trastuzumab
67
Leucovorin
64
Cytarabine
57
Methotrexate
52
Oxaliplatin
49
atezolizumab
48
Lenalidomide
43
Ipilimumab
40
Filgrastim
40
Bortezomib
39
Sorafenib
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 3
×
Has results
×
AZD 6244
×
Clear all
NCT04924608
2026-03-23
KOMET
AstraZeneca
Phase 3
Active not recruiting
145 enrolled
17 charts
1 FDA
NCT01933932
2025-11-19
SELECT-1
AstraZeneca
Phase 3
Active not recruiting
510 enrolled
16 charts
NCT01843062
2019-08-28
ASTRA
AstraZeneca
Phase 3
Terminated
233 enrolled
14 charts
NCT01974752
2017-01-05
SUMIT
AstraZeneca
Phase 3
Completed
152 enrolled
14 charts